![]() | Only 14 pages are availabe for public view |
Abstract Angiogenesis is a vital component of normal homeostasis: it is a fundamental biological process involved in reproduction & wound healing & is controlled by a complex series of ordered, self-limited process, which eventuates in the development of new vascular network. In normal angiogenesis, the ”on” and ”off” switches that control these complex processes are tightly regulated, maintaining a balance between pro- and antiangiogenic factors. However, defective or uncontrolled angiogenesis plays a critical role in inflammatory and neoplastic dermatologic disorders, including skin cancer, psoriasis, hemangiomas, Kaposi’s sarcoma, pyogenic granulomas, hypertrophic scar, and keloid. A better understanding of angiogenesis in normal and disease state is likely to provide new therapeutic approaches to improve wound healing, arrest the development of skin cancers, and prevent or treat inflammatory Skin disease. Antiangiogenic agents have recently been applied to dermatological disease with promising efficacy. The long- term side effects of antiangiogenic therapies are undetermined. Further research will determine the role of these agents in dermatology, and may faster development and implementation of novel and effective dermatologic therapeutics. Gene therapy is one of the novel and promising approaches for therapeutic intervention of cancer and under trials. Also one such promising angiogenic approach is to target and inhibit angiogenesis with vaccines. Recent advances and future prospects in vaccines are targeting aberrant angiogenesis of tumors. To date, several promising anti-angiogenic vaccine strategies have demonstrated marked inhibition of tumor growth in pre-clinical trials with some showing no observed interference with physiologic angiogenic processes such as wound healing and fertility. |